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Abstract: 
Background: Bioreactance is a novel non-invasive method for cardiac output measurement 
that involves the analysis of blood flow-dependent changes in the phase shifts of electrical 
currents applied across the chest. The present study evaluated the test-retest reliability of 
bioreactance for assessing hemodynamic variables at rest and during exercise.   
Methods: 22 healthy participants (26 (4) years) performed an incremental cycle ergometer 
exercise protocol relative to their individual power output at maximal O2 consumption 
(Wmax) on two separate occasions (trials 1 and 2). Participants cycled for five 3 min stages 
at 20, 40, 60, 80 and 90% Wmax. Haemodynamic and cardiorespiratory variables were 
assessed at rest and continuously during the exercise protocol. 
Results: Cardiac output was not significantly different between trials at rest (p = 0.948) nor at 
any stage of the exercise protocol (all p > 0.30). There was a strong relationship between 
cardiac output estimates between the trials (ICC = 0.95, p < 0.001) and oxygen consumption 
(ICC = 0.99, p < 0.001). Stroke volume was also not significantly different between trials at 
rest (p = 0.989) or during exercise (all p > 0.15), and strong relationships between trials were 
found (ICC = 0.83, p < 0.001).  
Conclusions: The bioreactance method demonstrates good test-retest reliability for estimating 
cardiac output at rest and during different stages of graded exercise testing including maximal 
exertion. 
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Introduction 1 
Monitoring of cardiac output (CO) has wide clinical application in anesthesiology, 2 
emergency care and cardiology. It can improve outcomes, establish diagnosis, guide therapy 3 
and help risk stratification in different clinical groups1. Measurement of cardiac output is 4 
essential in critically ill, injured and unstable patients as it provides an indication of systemic 5 
oxygen delivery and global tissue perfusion2. Cardiac output monitoring during surgery is 6 
associated with reduced length of hospital stay and postoperative complications3-5. 7 
Measurement of cardiac output under pharmacological and physiological stimulations defines 8 
overall function and performance of the heart, predicts prognosis and survival in heart failure 9 
can help explain the mechanisms of exercise intolerance, and improves risk stratification6-10. 10 
  11 
Thermodilution and direct Fick11-13 remain the “gold standard” and reference methods for 12 
assessing CO. Whilst “gold standard” these methods have inherent limitations as they are 13 
invasive, costly, require specialist skills and associated with noteworthy risks and 14 
complications such as catheter-related infections, arrhythmias and bleeding14 15. The 15 
risk:benefit ratio of these assessment methods has also been brought into question14. These 16 
limitations preclude the use of invasive cardiac output monitoring in large number of patients 17 
limiting the application of this useful diagnostic and prognostic marker. 18 
 19 
Over the previous decades several minimally invasive and non-invasive methods for 20 
assessing cardiac output have been developed including; trans-esophageal Doppler, 21 
transpulmonary thermodilution, pulse contour and pulse power analysis, and non-invasive 22 
techniques such as CO2 and inert gas rebreathing, transthoracic Doppler, thoracic 23 
bioimpedance cardiography, and electrical velocimetry (modified bioimpedance)2 16-18. 24 
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Unfortunately whilst these methods are safe they are associated with certain limitations 1 
precluding their accuracy and reliability13 19. 2 
 3 
Bioreactance, a novel method for continuous non-invasive cardiac output monitoring, has 4 
received increased attention in clinical and research practice in the recent years. The 5 
bioreactance method estimates CO by analysing the frequency of relative phase shift of 6 
electronic current across the thorax20 21. In contrast to impedance cardiography which is based 7 
on the analysis of transthoracic voltage amplitude changes in response to high frequency 8 
current, the bioreactance analyses the frequency spectra variations of the delivered oscillating 9 
current20. This approach is supposed to result in the improved precision of the bioreactance 10 
system as demonstrated by a 100 fold larger signal-to-noise ratio than that of bioimpedance 11 
and thus make it less susceptible to interference from adipose tissue, electrode placement and 12 
excessive movement20 22. 13 
 14 
The ability of bioreactance to monitor rapid changes in blood flow has recently been 15 
confirmed by Marik, et al.23. The authors compared carotid Doppler against bioreactance in 16 
patients with unstable cardiac conditions during passive leg raising. A strong correlation was 17 
reported in blood flow between the two methods in critically ill patients, with an accelerated 18 
response to these volume changes reported by bioreactance. Bioreactance cardiac output 19 
monitoring has been used in intensive care unit, during and following cardiac surgery, 20 
patients with chronic obstructive pulmonary disease and healthy individuals19 20 22-25. Other 21 
studies demonstrated that bioreactance measurements of cardiac output at rest and during 22 
exertion can identify cardiovascular function abnormalities, indexing disease severity, help 23 
prognosis and risk stratification, and track responses to treatment in clinical practice26 27.  24 
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When assessing cardiac output at rest or during physiological challenge, it is essential that 1 
method demonstrates acceptable level of reliability i.e. test-retest reliability which refers to 2 
the reproducibility of values of a variable when measured the same subjects twice. This is 3 
important because even small changes in cardiac output and stroke volume may have 4 
significant clinical implications when evaluating the effect of pharmacological and non-5 
pharmacological interventions and risk stratification. Based on available literature, it appears 6 
that test-retest reliability of bioreactance, as a novel and potent method for non-invasive 7 
continuous cardiac output monitoring has not been evaluated. Based on higher signal-to-noise 8 
ratio and improved performance19 20 we hypothesize that bioreactance method demonstrates 9 
acceptable test-retest reliability for evaluating cardiac output at rest and during physiological 10 
stimulation such as graded exercise testing. Additionally, we evaluated association between 11 
cardiac output and oxygen consumption at peak exercise.         12 
 13 
Methods 14 
All experimental procedures were approved by the Faculty’s Research Ethics Committee in 15 
accordance with the Declaration of Helsinki. In all cases, after being informed of the benefits 16 
and potential risks of the investigation all participants completed a standardised health-17 
screening questionnaire, undertook a resting electrocardiogram and gave their written 18 
informed consent. 19 
 20 
Twenty two healthy individuals (10 males and 12 females) mean age  21 
 22 
participated in the study. All participants were non-smokers and free from any cardiac and 23 
respiratory disorders. All participants attended the exercise laboratory on 2 separate days, day 24 
1 involved an initial assessment of maximal aerobic capacity (?̇?O2max) and day 2 required 2 25 
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visits consisting of an incremental exercise cycle ergometer protocol at individual pre-1 
determined workloads based on participants power output at ?̇?O2max (Wmax). Participants 2 
were required to abstain from eating for a minimum of 2 hours prior to the commencement of 3 
each test and from vigorous exercise 24 hours prior to the test. Participants were also 4 
instructed not to consume alcohol and caffeine containing foods and beverages on test days. 5 
 6 
Participants completed a maximal progressive exercise test on an electro-magnetically braked 7 
recumbent cycle ergometer (Corival, Lode, Groningen, Netherlands). All participants began 8 
cycling against a resistance of 40 W, this increased continually throughout the test at a ramp 9 
rate of 15 W min-1. Cessation of the assessment occurred when participants reached volitional 10 
exhaustion or were unable to maintain a cadence of 60-70 revolutions per minute. It was 11 
considered that a maximal effort was achieved if participants met any of two of the following 12 
criteria: i) a change in ?̇?O2 < 2 ml kg min-1 across two stages of the incremental test; ii) a 13 
respiratory exchange ratio of 1.15 or greater, or iii) ≥ 90% age predicted maximum heart rate 14 
(220-age)28. Expired gases were measured via online metabolic gas exchange system (Cortex 15 
metalyser 3B, Leipzig, Germany) and heart rate was measured via short range telemetry 16 
(Polar RS400, Finland). Peak oxygen consumption was defined as the average oxygen uptake 17 
during the last minute of exercise, expressed as millilitres per kilogram of body weight per 18 
minute and litres per minute. The Wmax was defined as the power output expressed in W at 19 
the point at which participants reached their individual ?̇?O2max. 20 
 21 
Exercise protocol was performed twice on study day 2 with ≥ 3 h interval between trials 1 22 
and 2. Participants were required to complete five 3 min stages (equating to 15 min of cycling) 23 
at intensities relative to 20, 40, 60, 80 and 90% Wmax. Cardiac and hemodynamic responses 24 
including cardiac output, cardiac index, stroke volume and stroke volume index, and heart 25 
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rate were recorded at rest and throughout the incremental exercise protocol using a non-1 
invasive bioreactance system (NICOM®, Cheetah Medical, Delaware, USA). Simultaneously, 2 
respiratory and gas exchange measurements were recorded (Cortex metalyser 3B, Leipzig, 3 
Germany). 4 
 5 
The bioreactance system comprises of a radio frequency generator that creates a high 6 
frequency current that is introduced across the thoracic cavity. The NICOM® has been 7 
described previously19 20 25. It analyses the relative phase shift of electronic current across the 8 
thorax. In brief the four dual surface electrodes are used to establish electrical contact with 9 
the body. The skin was prepared by shaving where required and using adhesive paper to 10 
ensure an optimal signal from the electrodes. Two electrodes were placed over the trapezius 11 
muscle on either side of the upper torso and two on the lower posterior torso lateral to the 12 
margin of the latissimus dorsi musculature. The right and left sensors of the devise generate 13 
independent signals which are subsequently integrated to generate the final signal analysed. 14 
The blood that is present in the thoracic cavity absorbs electrons, which results in a delay in 15 
the signal, which is proportional to the volume of blood flow. This is called a phase shift and 16 
is recorded and the figure is translated to the flow of the blood. The signal that is detected by 17 
the electrodes is then processed separately and averaged after digital processing at 30 or 60 s 18 
intervals. The signal processing unit of the NICOM® determines the relative phase shift (∆φ) 19 
between the input signals relative to the output signal. The ∆φ is in response to any changes 20 
in blood flow that pass through the aorta. The CO is then derived by CO = (C x VET x ∆φ 21 
dtmax) x HR, where C is the constant of proportionality and VET is ventricular ejection 22 
fraction time19. The value of C has been previously validated to account for patient age, 23 
gender, height and weight22. CO can then be calculated from stroke volume and HR. 24 
 25 
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Statistical methods 1 
Statistical analyses were performed using PASW statistical analysis software (Version 19, 2 
IBM, USA). Data are presented as mean (standard deviation). The alpha level of 0.05 was set 3 
prior to data analysis and normality of distribution was assessed using a Kolmogorov-4 
Smirnov test. Relative reliability was determined using intra-class correlation coefficients 5 
(ICC), calculated using the two-way random method previously described by Weir29. 6 
Absolute reliability was determined using standard error of measurement (SEM) with 95% 7 
confidence intervals (95%CI), which were calculated independently of intra-class correlation 8 
coefficients. Systemic bias in the repeatability between trials was assessed using paired 9 
sample t-tests. The relationship between cardiac output and oxygen consumption was 10 
assessed with Pearson’s coefficient of correlation. Data analyses were performed on both 11 
combined resting and exercise data and data from each individual stage of the incremental 12 
exercise protocol for CO, cardiac index (CI), stoke volume (SV), stroke volume index (SVI), 13 
heart rate (HR) minute ventilation (VE) and oxygen consumption (?̇?O2). 14 
 15 
Results 16 
Physical characteristics of study participants are: age 26.3 (4.2) years, height 171.5 (8) cm, 17 
body mass 67.4 (7.9) kg, and peak oxygen consumption 41.5 (8.7) ml kg min-1. Data 18 
pertaining to the systemic bias between trials for all assessed cardiac and respiratory variables 19 
are presented in Table 1. There was a non-significant (< 5%) difference between trials 1 and 20 
2 for all variables (p > 0.05). 21 
 22 
Table 1 about here 23 
 24 
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Reliability statistics for cardiac and respiratory responses to the incremental exercise protocol 1 
are presented in Tables 2 and 3. These data demonstrate strong relative (Table 2) and test-2 
retest absolute (Table 3) reliability.  3 
 4 
Table 2 about here 5 
 6 
Cardiac output was similar between the trials 1 and 2 at rest (0.7 (10.3) %) and all stages of 7 
the incremental exercise protocol (Figure 1). At low exercise intensity i.e. 20-40% of Wmax 8 
the differences in cardiac output between trials 1 and 2 were 4 and 1%, respectively. At 9 
moderate (i.e. 60% of Wmax) and high (80 and 90% of Wmax) exercise intensity the 10 
difference was only between 1 and 2% (Figure 1).  11 
 12 
Table 3 about here 13 
 14 
Non-significant differences between the trial 1 and 2 were reported for stroke volume at all 15 
stages of the protocol, with mean difference ranging from 1% (at 80% of Wmax) to 7% (at 20% 16 
of Wmax, Figure 2). When resting and exercise data points are considered together (n=132), 17 
the mean difference between trial 1 and 2 was only 2%. 18 
 19 
Figure 1 about here 20 
 21 
Participants mean cardiac index and stroke volume index were not significantly different 22 
between the trials when data analyses included combined resting and exercise data (Table 1). 23 
Furthermore, neither mean cardiac index nor stroke volume index was significantly different 24 
between trials at rest or at any exercise stage. 25 
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 1 
Figure 2 about here 2 
 3 
As detailed in Table 1 heart rate, peak oxygen consumption, and mean ventilation were 4 
similar between trials. Relative and absolute reliability statistics presented in Tables 2 and 3 5 
demonstrate good reliability. In addition, no significant differences between the trials were 6 
found in heart rate, peak oxygen consumption, and mean ventilation at rest or at any of the 7 
exercise intensities (p > 0.05).  8 
 9 
Data demonstrate a strong relationship between cardiac output and oxygen consumption at 10 
peak exercise for both trials (Trial 1; r = 0.64, p = 0.001, Trial 2; r = 0.66, p < 0.001). 11 
 12 
Discussion 13 
The primary finding of this study is that bioreactance demonstrates acceptable test-retest 14 
reliability for estimating cardiac output and stroke volume at rest and during physiological 15 
stress induced by exercise testing. Additionally, the exercise protocol employed in the present 16 
study elicited similar cardiorespiratory responses between trials and a strong relationship was 17 
identified between cardiac output and peak oxygen consumption for both trials. This 18 
illustrates the ability of the exercise protocol to elicit reliable hemodynamic and 19 
cardiorespiratory responses on separate occasions in the absence of changes in health and 20 
clinical status of an individual. 21 
 22 
The assessment of cardiac output in a reliable manner is an essential tool to accurately assess 23 
any improvements or decrements in cardiac function of numerous patient groups. As 24 
previously stated this is of particular importance in cardiac patients as small changes in 25 
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cardiopulmonary data due to disease or intervention may have significant clinical 1 
implications30. It may therefore be suggested that inaccurate and unreliable measures may 2 
contribute to misinterpretation of data and potentially misdiagnosis. The excellent reliability 3 
of bioreactance in measuring haemodynamics (at rest and continuously during exercise) 4 
reported in the present study illustrates its potential clinical application. Furthermore, its 5 
ability to assess cardiac output noninvasively, inexpensively and without specialist training of 6 
the assessor permits its application in an increased number of patient groups when compared 7 
to more invasive and “gold standard” catheter based measurement techniques11 12.  8 
 9 
The CO values reported in the present study are consistent with recent research employing 10 
bioreactance in a comparable population and at similar exercise intensities19. The authors 11 
Jakovljevic, et al.19 reported resting CO values of 6.5 L min-1 which are similar to those 12 
reported in the present study. Similar values were also reported at comparable submaximal 13 
and near maximal exercise intensities. Furthermore the CO data previously reported19 was 14 
consistently correlated with CO estimates derived from measured oxygen consumption31. We 15 
have also demonstrated a strong relationship between cardiac output and oxygen 16 
consumption at peak exercise in the present study.  Elliott, et al.25 also reported similar CO as 17 
assessed via bioreactance at similar exercise intensities as the present study and previous 18 
study19. In addition resting and near maximal cardiac index reported in the present study is 19 
similar to that previously reported25.  The data presented in this article further substantiates 20 
the previous work19 25 and demonstrates that bioreactance is accurate and reliable for 21 
assessing haemodynamic variables at various exercise intensities. Furthermore, cardiac 22 
output data from the present study that are associated particularly with  stages of low to 23 
moderate intensities are consistent with those identified in different stages of heart failure26 27. 24 
Overall, data presented in the present study indicate that bioreactance can provide reliable 25 
10 
 
measures of cardiac output independent of any other physiological measures (e.g. oxygen 1 
consumption) and potential elevated electrical noise, body motion, perspiration and body 2 
temperature associated with graded exercise. 3 
 4 
The present study is not without limitations. Firstly, the study participants were young, 5 
healthy adults whereas older people and those with chronic conditions were not included. It 6 
may be speculated therefore that the present findings cannot be generalized to a wider, 7 
clinical applications. However, the study protocol allowed analysis of bioreactance cardiac 8 
output test-retest reliability not only at peak exercise but also at low to moderate levels of 9 
exercise intensities that are often observed in individuals with chronic conditions and in older 10 
people. Secondly, no gold standard for cardiac output measurement (i.e. thermodilution or 11 
direct Fick) was included. The additional risks posed to the study participants with these 12 
procedures precluded them from being undertaken. 13 
 14 
Conclusions 15 
In conclusion, bioreactance method demonstrates good test-retest reliability for estimating 16 
cardiac output and stroke volume at rest and during different stages of graded exercise testing 17 
including maximal exertion. Future large studies are warranted to assess the reliability of 18 
bioreactance at both rest and exercise in different clinical groups where monitoring of cardiac 19 
output has been shown to improve risk stratification and clinical outcomes.  20 
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Tables 1 
Table 1. The mean values and standard deviations for cardiac and respiratory variables 2 
obtained at rest and during the incremental exercise protocol.  3 
 4 
Variable Trial 1 Trial 2 t-test (p-value) 
Cardiac output  
(L min-1) 
13.7 (4.4)  13.4 (4.1)  0.518 
Heart rate  
(beats min-1) 
123.7 (37.8) 124.3 (36.7) 0.905 
Stroke volume  
(ml beat-1) 
112.9 (22.5) 109.5 (18.7) 0.179 
Minute ventilation  
(L min-1) 
46.2 (30.0) 47.6 (30.3) 0.732 
Oxygen 
consumption  
(L min-1) 
1.6 (0.9) 1.6 (0.9) 0.882 
Note: p value determined from test-retest data using paired sample t-test for measurement 5 
outcomes. Data analyses performed on resting and exercise data combined (n = 22, data 6 
points =132).  7 
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Table 2. Relative reliability statistics for cardiac and respiratory variables at rest and during 1 
the incremental exercise protocol. 2 
 3 
Variable ICC 
Cardiac output  
(L min-1) 
0.95*  
Heart rate  
(beats min-1) 
0.99* 
Stroke volume  
(ml beat-1) 
0.88* 
Minute ventilation  
(L min-1) 
0.99* 
Oxygen consumption  
(L min-1) 
0.99* 
*Significant correlation between trials 1 and 2 (p < 0.001). Data analyses performed on 4 
resting and exercise data combined (n = 22, data points =132). 5 
  6 
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Table 3. Absolute reliability statistics for cardiac and respiratory variables at rest and during 1 
the incremental exercise protocol. 2 
 3 
Variable 
Change in mean 
(%) 
95%CI Sx SRD 
Cardiac output  
(L min-1) 
11.1 ±0.7 ±3.0 1.2 
Heart rate  
(beats min-1) 
6.7 ±6.4 ±26.3 10.3 
Stroke volume  
(ml beat-1) 
9.8 ±3.5 ±14.6 5.7 
Minute ventilation  
(L min-1) 
12.0 ±5.4 ±21.3 8.4 
Oxygen consumption  
(L min-1) 
12.1 ±0.2 ±0.7 0.3 
Note: Sx = standard error of the mean, SD = standard deviation, SRD = smallest real 4 
difference. Data analyses performed on resting and exercise data combined (n = 22, data 5 
points =132). 6 
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Figure legends 1 
Figure 1.  Mean cardiac output at rest and at individual stages of the incremental exercise 2 
protocol on trials 1 and 2. Wmax = power output in Watts (W) at ?̇?O2max (n = 22). 3 
 4 
Figure 2.  Mean stroke volume at rest and at individual stages of the incremental exercise 5 
protocol on trials 1 and 2. Wmax = power output in Watts (W) at ?̇?O2max (n = 22). 6 
